Abstract
Opioid analgesics represent a major therapeutic approach to pain management but challenge clinicians and healthcare systems for appropriate usage and long-term patient benefits. Opioids can be full agonists and partial agonists–antagonists for therapeutic effects that involve the mu, kappa, and delta opioid receptors. Opioids can be administered by different routes that include intravenous, intramuscular, oral, sublingual, transdermal, nasal spray, and rectal suppositories. Opioids can be short-acting and medium-acting agents based upon their elimination half-life that requires multiple daily dosing regimens. Sustained-release formulations have been developed for several opioids. The transdermal formulation allows for once-daily application. Some opioids are metabolized by the CYP enzyme system, while other opioids are primarily metabolized via glucuronidation. Depending upon the opioid, these agents are metabolized to active metabolites that possess analgesic effects that can be greater than, equal to, or less than the parent drug. Morphine has been the prototypical opioid analgesic agent and its pharmacokinetic and pharmacodynamic profile extensively studied in various patient populations. Besides their therapeutic analgesic effects, opioids can produce a variety of adverse effects related to their pharmacokinetic and pharmacodynamic actions that includes physical dependence, tolerance, respiratory depression, cardiovascular effects, sedation, cognitive impairment, gastrointestinal effects, histamine effects, and miosis. An integrated pharmacokinetic–pharmacodynamic approach to opioid treatment can lead to its optimal pharmacotherapy.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Portenoy RK, Ahmed E (2014) Principles of opioid use in cancer pain. J Clin Oncol 32(16):1662–1670
Trescot AM, Datta S, Lee M, Hansen H (2008) Opioid pharmacology. Pain Physician 11(2 Suppl):S133–S153
Lin JH, Yamazaki M (2003) Role of P-glycoprotein in pharmacokinetics: clinical implications. Clin Pharmacokinet 42(1):59–98
Mercer SL, Coop A (2011) Opioid analgesics and P-glycoprotein efflux transporters: a potential systems-level contribution to analgesic tolerance. Curr Top Med Chem 11(9):1157–1164
Eap CB, Buclin T, Baumann P (2002) Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. Clin Pharmacokinet 41(14):1153–1193
Gourevitch MN, Hartel D, Tenore P et al (1999) Three oral formulations of methadone. A clinical and pharmacodynamic comparison. J Subst Abuse Treat 17(3):237–241
Lee CR, McTavish D, Sorkin EM (1993) Tramadol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in acute and chronic pain states. Drugs 46(2):313–340
Grond S, Sablotzki A (2004) Clinical pharmacology of tramadol. Clin Pharmacokinet 43(13):879–923
Benziger DP, Kaiko RF, Miotto JB, Fitzmartin RD, Reder RF, Chasin M (1996) Differential effects of food on the bioavailability of controlled-release oxycodone tablets and immediate-release oxycodone solution. J Pharm Sci 85(4):407–410
Streisand JB, Varvel JR, Stanski DR et al (1991) Absorption and bioavailability of oral transmucosal fentanyl citrate. Anesthesiology 75(2):223–229
Findlay JW, Butz RF, Welch RM (1977) Codeine kinetics as determined by radioimmunoassay. Clin Pharmacol Ther 22(4):439–446
Kim I, Barnes AJ, Oyler JM et al (2002) Plasma and oral fluid pharmacokinetics and pharmacodynamics after oral codeine administration. Clin Chem 48(9):1486–1496
Rowell FJ, Seymour RA, Rawlins MD (1983) Pharmacokinetics of intravenous and oral dihydrocodeine and its acid metabolites. Eur J Clin Pharmacol 25(3):419–424
Inturrisi CE, Max MB, Foley KM, Schultz M, Sin S-U, Houde RW (1984) The pharmacokinetics of heroin in patients with chronic pain. N Engl J Med 310(19):1213–1217
Valtier S, Bebarta VS (2012) Excretion profile of hydrocodone, hydromorphone and norhydrocodone in urine following single dose administration of hydrocodone to healthy volunteers. J Anal Toxicol 36:507–514, Jul 10:bks058
Vallner JJ, Stewart JT, Kotzan JA, Kirsten EB, Honigberg IL (1981) Pharmacokinetics and bioavailability of hydromorphone following intravenous and oral administration to human subjects. J Clin Pharmacol 21(4):152–156
Dixon R, Crews T, Inturrisi C, Foley K (1983) Levorphanol: pharmacokinetics and steady-state plasma concentrations in patients with pain. Res Commun Chem Pathol Pharmacol 41(1):3–17
Edwards D, Svensson CK, Visco JP, Lalka D (1982) Clinical pharmacokinetics of pethidine: 1982. Clin Pharmacokinet 7(5):421–433
Mather LE, Meffin PJ (1978) Clinical pharmacokinetics pethidine. Clin Pharmacokinet 3(5):352–368
Osborne R, Joel S, Trew D, Sleven M (1990) Morphine and metabolite behavior after different routes of administration: demonstration of the importance of the active metabolite morphine-6-glucuronide. Clin Pharmacol Ther 47(1):12–19
Sawe J, Dahlstrom B, Paalzow L, Rane A (1981) Morphine kinetics in cancer patients. Clin Pharmacol Ther 30:629–635
Sawe J, Svensson JO, Rane A (1983) Morphine metabolism in cancer patients on increasing oral doses – no evidence for autoinduction or dose-dependence. Br J Clin Pharmacol 16(1):85–93
Sawe J (1986) High dose morphine and methadone in cancer patients. Clinical pharmacokinetic considerations on oral treatment. Clin Pharmacokinet 11(2):87–106
Hoskin PJ, Hanks GW, Aherne GW, Chapman D, Littleton P, Filshie J (1989) The bioavailability and pharmacokinetics of morphine after intravenous, oral and buccal administration in healthy volunteers. Br J Clin Pharmacol 27(4):499–505
Gourlay GK, Cherry DA, Cousins MJ (1986) A comparative study of the efficacy and pharmacokinetics of oral methadone and morphine in the treatment of severe pain in patients with cancer. Pain 25(3):297–312
Pöyhiä R, Seppälä T, Olkkola KT, Kalso E (1992) The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects. Br J Clin Pharmacol 33(6):617–621
Smith HS (2009) Clinical pharmacology of oxymorphone. Pain Med 10(1 Suppl):S3–S10, Oxymorphone
Lintz W, Barth H, Osterloh G, Schmidt-Böthelt E (1986) Bioavailability of enteral tramadol formulations. 1st communication: capsules. Arzneimittel Forschung 36(8):1278–1283
Bullingham RES, McQuay HJ, Porter EJB, Allen MC, Moore RA (1982) Sublingual buprenorphine used postoperatively: ten hour plasma drug concentration analysis. Br J Clin Pharmacol 13(5):665–673
Pachter IJ, Evens RP (1985) Butrophanol. Drug Alcohol Depend 14(3):325–338
Inturrisi CE (2002) Clinical pharmacology of opioids for pain. Clin J Pain 18(4 Suppl):S3–S13
Wood M (1986) Plasma drug binding: implications for anesthesiologists. Anesth Analg 65(7):786–804
Lemmens HJ (1995) Pharmacokinetic-pharmacodynamic relationships for opioids in balanced anaesthesia. Clin Pharmacokinet 29(4):231–242
Gulaboski R, Cordeiro MN, Milhazes N et al (2007) Evaluation of the lipophilic properties of opioids, amphetamine-like drugs, and metabolites through electrochemical studies at the interface between two immiscible solutions. Anal Biochem 361(2):236–243
Lombardo F, Shalaeva MY, Tupper KA, Gao F (2001) ElogD(oct): a tool for lipophilicity determination in drug discovery. 2. Basic and neutral compounds. J Med Chem 44(15):2490–2497
Garrett ER, Chandran VR (1985) Pharmacokinetics of morphine and its surrogates VI: bioanalysis, solvolysis kinetics, solubility, pK’a values, and protein binding of buprenorphine. J Pharm Sci 74(5):515–524
Vree TB, Wissen CPWGMV-V (1992) Pharmacokinetics and metabolism of codeine in humans. Biopharm Drug Dispos 13(6):445–460
Quiding H, Anderson P, Bondesson U, Boréus LO, Hynning P-Å (1986) Plasma concentrations of codeine and its metabolite, morphine, after single and repeated oral administration. Eur J Clin Pharmacol 30(6):673–677
Gasche Y, Daali Y, Fathi M et al (2004) Codeine intoxication associated with ultrarapid CYP2D6 metabolism. N Engl J Med 351(27):2827–2831
Moolenaar F, Grasmeuer G, Visser J, Meijer DKF (1983) Rectal versus oral absorption of codeine phosphate in man. Biopharm Drug Dispos 4(2):195–199
Kirkwood LC, Nation RL, Somogyi AA (1997) Characterization of the human cytochrome P450 enzymes involved in the metabolism of dihydrocodeine. Br J Clin Pharmacol 44(6):549–555
Ammon S, Hofmann U, Griese E-U, Gugeler N, Mikus G (1999) Pharmacokinetics of dihydrocodeine and its active metabolite after single and multiple oral dosing. Br J Clin Pharmacol 48(3):317–322
Fromm MF, Hofmann U, Griese E-U, Mikus G (1995) Dihydrocodeine: a new opioid substrate for the polymorphic CYP2D6 in humans. Clin Pharmacol Ther 58(4):374–382
Davies KN, Castleden CM, McBurney A, Jagger C (1989) The effect of ageing on the pharmacokinetics of dihydrocodeine. Eur J Clin Pharmacol 37(4):375–379
Cohn GL, Cramer JA, McBride W, Brown RC, Kleber HD (1974) Heroin and morphine binding with human serum proteins and red blood cells. Exp Biol Med 147(3):664–666
Giardin F, Rentsch KM, Schwab M-A et al (2003) Pharmacokinetics of high doses of intramuscular and oral heroin in narcotic addicts. Clin Pharmacol Ther 74(4):341–352
Rook EJ, Huitema ADR, van den Brink W, van Ree JM, Beijnen JH (2006) Population pharmacokinetics of heroin and its major metabolites. Clin Pharmacokinet 45(4):401–417
Yeh SY, Gorodetzky CR, McQuinn RL (1976) Urinary excretion of heroin and its metabolites in man. J Pharmacol Exp Ther 196(2):249–256
Cone EJ, Darwin WD, Gorodetzky CW, Tan T (1978) Comparative metabolism of hydrocodone in man, rat, guinea pig, rabbit, and dog. Drug Metab Dispos 6(4):488–493
Otton S, Schadel M, Cheung SW, Kaplan HL, Busto UE, Sellers EM (1993) CYP2D6 phenotype determines the metabolic conversion of hydrocodone to hydromorphone. Clin Pharmacol Ther 54(5):463–472
Ritschel W, Parab PV, Denson DD, Coyle DE, Gregg RV (1987) Absolute bioavailability of hydromorphone after peroral and rectal administration in humans: saliva/plasma ratio and clinical effects. J Clin Pharmacol 27(9):647–653
Murray A, Hagen NA (2005) Hydromorphone. J Pain Symptom Manage 29(5):57–66
Parab PV, Ritschel WA, Coyle DE, Gregg RV, Denson DD (1988) Pharmacokinetics of hydromorphone after intravenous, peroral and rectal administration to human subjects. Biopharm Drug Dispos 9(2):187–199
Dilaudid and Dilaudid-HP Injection (hydromorphone hydrochloride). Prescribing information. Manufactured by Hospira, Inc., Lake Forest, IL 60045, USA for Purdue Pharma L.P. Stamford, CT 06901–3431. Revised June 2008
Umans JG, Inturrisi CE (1982) Antinociceptive activity and toxicity of meperidine and normeperidine in mice. J Pharmacol Exp Ther 223(1):203–206
Kirkwood CF, Edwards DJ, Lalka D, Lasezkay G, Hassett JM, Slaughter RL (1986) The pharmacokinetics of meperidine in acute trauma patients. J Trauma 26(12):1090–1093
Inturrisi CE, Colburn WA, Kaiko RF, Houde RW, Foley KM (1987) Pharmacokinetics and pharmacodynamics of methadone in patients with chronic pain. Clin Pharmacol Ther 41(4):392–401
Oda Y, Kharasch ED (2001) Metabolism of methadone and levo-α-acetylmethadol (LAAM) by human intestinal cytochrome P450 3A4 (CYP3A4): potential contribution of intestinal metabolism to presytemic clearance and bioactivation. J Pharmacol Exp Ther 298(3):1021–1032
Wolff K, Rostami-Hodjegan A, Shires S, Hay AWM, Feely M, Calvert R, Raistrick D, Tucher GT (1997) The pharmacokinetics of methadone in healthy subjects and opiate users. Br J Clin Pharmacol 44:325–334
Nilsson M-I, Widerlöv E, Meresaar U, Änggåard E (1982) Effect of urinary pH on the disposition of methadone in man. Eur J Clin Pharmacol 22(4):337–342
Olsen GD, Bennett WM, Porter GA (1975) Morphine and phenytoin binding to plasma proteins in renal and hepatic failure. Clin Pharmacol Ther 17(6):677–684
Yeh SY, Gorodetzky CW, Krebs HA (1977) Isolation and identification of morphine 3- and 6-glucuronides, morphine 3,6-diglucuronide, morphine 3-ethereal sulfate, normorphine, and normorphine 6-glucuronide as morphine metabolites in humans. J Pharm Sci 66(9):1288–1293
Cone EJ, Huestis MA (2007) Interpretation of oral fluid tests for drugs of abuse. Ann N Y Acad Sci 1098(1):51–103
Pöyhiä R, Vainio A, Kalso E (1993) A review of oxycodone’s clinical pharmacokinetics and pharmacodynamics. J Pain Symptom Manage 8(2):63–67
Lalovic B, Kharasch E, Hoffer C, Risler L, Liu-Chen L-Y, Shen DD (2006) Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: role of circulating active metabolites. Clin Pharmacol Ther 79(5):461–479
Adams MP, Ahdieh H (2005) Single- and multiple-dose pharmacokinetic and dose-proportionality study of oxymorphone immediate-release tablets. Drugs R D 6:91–99
Adams MP, Ahdieh H (2004) Pharmacokinetics and dose‐proportionality of oxymorphone extended release and its metabolites: results of a randomized crossover study. Pharmacother J Human Pharmacol Drug Ther 24(4):468–476
Cone EJ, Darwin WD, Buchwald WF, Gorodetzky CW (1983) Oxymorphone metabolism and urinary excretion in human, rat, guinea pig, rabbit and dog. Drug Metab Dispos 11(5):446–450
Lee CR, McTavish D, Sorkin EM (1993) Tramadol: a preliminary review of its pharmacodynamics and pharmacokinetic properties, and therapeutic potential in acute and chronic pain states. Drugs 46(2):313–340
Lintz W, Erlacin S, Frankus E et al (1981) Biotransformation of tramadol in man and animal (in German). Arzneimittel Forschung 31(11):1932–1943
Paar WD, Poche S, Gerloff J, Dengler HJ (1997) Polymorphic CYP2D6 mediates O-demethylation of the opioid analgesic tramadol. Eur J Clin Pharmacol 53(3–4):235–239
Meuldermens W, Woestenborghs R, Noorduin H, Cmu F, van Steenberge A, Heykants J (1986) Protein binding of the analgesics alfentanil and sufentanil in maternal and neonatal plasma. Eur J Clin Pharmacol 30(2):217–219
Meuldermans W, Van Peer A, Hendrickx J et al (1988) Alfentanil pharmacokinetics and metabolism in humans. Anesthesiology 69(4):527–534
Labroo RB, Thummel KE, Lunze KL, Podoll T, Trager WF, Kharasch ED (1995) Catalytic role of cytochrome P4503A4 in multiple pathways of alfentanil metabolism. Drug Metab Dispos 23(4):490–496
Scholz J, Steinfath M, Schulz M (1996) Clinical pharmacokinetics of alfentanil, fentanyl and sufentanil, an update. Clin Pharmacokinet 31(4):275–292
Meuldermans WEB, Hurkmans RMA, Heykants JJP (1982) Plasma protein binding and distribution of fentanyl, sufentanil, alfentanil and lofentanil in blood. Arch Int Pharmacodyn Ther 257(1):4–19
McClain DA, Hug CC (1980) Intravenous fentanyl kinetics. Clin Pharmacol Ther 28(1):106–114
Labroo RB, Paine MF, Thummel KE, Kharasch ED (1997) Fentanyl metabolism by human hepatic and intestinal cytochrome P450 3A4: implications for interindividual variability in disposition, efficacy, and drug interactions. Drug Metab Dispos 25(9):1072–1080
Bovill JG, Sebel PS (1980) Pharmacokinetics of high-dose fentanyl. Br J Anaesth 52(8):795–801
Glass PSA, Gan TJ, Scott H (1999) A review of the pharmacokinetics and pharmacodynamics of remifentanil. Anesth Analg 89(4 Suppl):7
Egan TD, Lemmens HJM, Fiset P et al (1993) The pharmacokinetics of the new short-acting opioid remifentanil (GI87084B) in healthy adult male volunteers. Anesthesiology 79(5):881–892
Glass PSA, Hardman D, Kamiyama Y et al (1993) Preliminary pharmacokinetics and pharmacodynamics of an ultra-short-acting opioid: remifentanil (GI87084B). Anesth Analg 77(5):1031–1040
Westmoreland CL, Hoke JF, Sebe PS, Hug CC, Muir KT (1993) Pharmacokinetics of remifentanil (GI87084B) and its major metabolite (GI90291) in patients undergoing elective inpatient surgery. Anesthesiology 79(5):893–903
Bovill JG, Seel PS, Blackburn CL, Oei-Lim V, Heykants JJ (1984) The pharmacokinetics of sufentanil in surgical patients. Anesthesiology 61(5):502–506
Tateishi T, Krivoruk Y, Ueng Y-F, Wood AJJ, Guengerich FP, Wood M (1996) Identification of human liver cytochrome P-450 3A4 as the enzyme responsible for fentanyl and sufentanil N-dealkylation. Anesth Analg 82(1):167–172
Scholz J, Bause H, Schulz M et al (1994) Pharmacokinetics and effects on intracranial pressure of sufentanil in head trauma patients. Br J Clin Pharmacol 38(4):369–372
Garrett ER, Chandran VR (1985) Pharmacokinetics of morphine and its surrogates VI: bioanalysis, solvolysis kinetics, solubility, pKa values, and protein binding of buprenorphine. J Pharm Sci 74(5):515–524
Kuhlman JJ, Lalani S, Magluilo J et al (1996) Human pharmacokinetics of intravenous, sublingual, and buccal buprenorphine. J Anal Toxicol 20(6):369–378
Cone EJ, Gorodetzky CW, Yousefnejad D, Buchwald W, Johnson RE (1984) The metabolism and excretion of buprenorphine in humans. Drug Metab Dispos 12(5):577–581
Gaver RC, Vasijev M, Wong H et al (1980) Disposition of parenteral butorphanol in man. Drug Metab Dispos 8(4):230–235
Shyu WC, Pittman KA, Robinson DS, Barbhaiya RH (1993a) The absolute bioavailability of transnasal butorphanol in patients experiencing rhinitis. Eur J Pharmacol 45(6):559–562
van Dorp EL, Romberg R, Sarton E, Bovill JG, Dahan A (2006) Morphine-6-glucuronide: morphine’s successor for postoperative pain relief? Anesth Analg 102(6):1789–1797
Wasan AD, Michna E, Janfaza D, Greenfield S, Teter CJ, Jamison RN (2008) Interpreting urine drug tests: prevalence of morphine metabolism to hydromorphone in chronic pain patients treated with morphine. Pain Med 9(7):918–923
Somogyi AA, Barratt DT, Coller JK (2007) Pharmacogenetics of opioids. Clin Pharmacol Ther 81(3):429–444
Sadhasivam S, Chidambaran V (2012) Pharmacogenomics of opioids and perioperative pain management. Pharmacogenomics 13(15):1719–1740
Gasche Y, Daali Y, Fathi M et al (2004) Codeine intoxication associated with ultrarapid CYP2D6 metabolism. N Engl J Med 351(27):2827–2831
Kaplan HL, Busto UE, Baylon GJ et al (1997) Inhibition of cytochrome P450 2D6 metabolism of hydrocodone to hydromorphone does not importantly affect abuse liability. J Pharmacol Exp Ther 281(1):103–108
Murtagh FE, Chai MO, Donohoe P, Edmonds PM, Higginson IJ (2007) The use of opioid analgesia in end-stage renal disease patients managed without dialysis: recommendations for practice. J Pain Palliat Care Pharmacother 21(2):5–16
Mercadante S, Arcuri E (2004) Opioids and renal function. J Pain 5(1):2–19
Filitz J, Griessinger N, Sittl R, Likar R, Schüttler J, Koppert W (2006) Effects of intermittent hemodialysis on buprenorphine and norbuprenorphine plasma concentrations in chronic pain patients treated with transdermal buprenorphine. Eur J Pain 10(8):743–748
Hand CW, Sear JW, Uppington J, Ball MJ, McQuay HJ, Moore RA (1990) Buprenorphine disposition in patients with renal impairment: single and continuous dosing, with special reference to metabolites. Br J Anaesth 64(3):276–282
Kestenbaum MG, Vilches AO, Messersmith S et al (2014) Alternative routes to oral opioid administration in palliative care: a review and clinical summary. Pain Med 15(7):1129–1153
Nestorov I (2003) Whole body pharmacokinetic models. Clin Pharmacokinet 42(10):883–908
Mathias NR, Hussain MA (2010) Non-invasive systemic drug delivery: developability considerations for alternate routes of administration. J Pharm Sci 99(1):1–20
Plosker GL (2011) Buprenorphine 5, 10 and 20 μg/h transdermal patch. A review of its use in the management of chronic nonmalignant pain. Drugs 71(18):2491–2509
Shyu WC, Mayol RF, Pfeffer M, Pittman KA, Gammans RE, Barbhaiya RH (1993b) Biopharmaceutical evaluation of transnasal, sublingual, and buccal disk dosage forms of butorphanol. Biopharm Drug Dispos 14(5):371–379
Lötsch J, Walter C, Parnham MJ, Oertel BG, Geisslinger G (2013) Pharmacokinetics of non-intravenous formulations of fentanyl. Clin Pharmacokinet 52(1):23–36
Exalgo (hydromorphone HCl) Extended-Release Tablets. Prescribing Information. Mallinckrodt Brand Pharmaceutical, Inc. Hazelwood, MO 63042. Revised: April 2014
Babul N, Darke AC (1993) Disposition of morphine and its glucuronide metabolites after oral and rectal administration: evidence of route specificity. Clin Pharmacol Ther 54(3):286–292
Lintz W, Barth H, Osterloh G, Smith-Böthelt E (1998) Bioavailability of enteral tramadol formulations. 3rd communication: suppositories. Arzneimittel Forschung 48(9):889–899
Panagiotou I, Mystakidou K (2010) Intranasal fentanyl: from pharmacokinetics and bioavailability to current treatment applications. Expert Rev Anticancer Ther 10(7):1009–1021
Lane ME (2013) The transdermal delivery of fentanyl. Eur J Pharm Biopharm 84(3):449–455
Grond S, Radbruch L, Lehmann KA (2000) Clinical pharmacokinetics of transdermal opioids: focus on transdermal fentanyl. Clin Pharmacokinet 38(1):59–89
Beaver WT, Feise GA (1977) A comparison of the analgesic effect of oxymorphone by rectal suppository and intramuscular injection in patients with postoperative pain. J Clin Pharmacol 17(5–6):276–291
IUPHAR/BPS Guide to Pharmacology. Available at: www.guidetopharmacology.org. Last accessed on 23 Mar 2015
Volpe DA, McMahon Tobin GA, Mellon RD et al (2011) Uniform assessment and ranking of opioid μ receptor binding constants for selected opioid drugs. Regul Toxicol Pharmacol 59(3):385–390
Yaksh T, Wallace M (2014) Chapter 18: Opioids, analgesia, and pain management. In: Goodman & Gilman’s the pharmacological basis of therapeutics, 12th ed. The Mc Graw Hill Company, Inc. (e-version). McGraw-Hill publishing, Boston, MA.
Olkkola KT, Kontinen VK, Saari TI, Kalso EA (2013) Does the pharmacology of oxycodone justify its increasing use as an analgesic? Trends Pharmacol Sci 34(4):206–214
Washington State Agency Medical Directors’ Group. Opioid dose calculator. Available at: http://agencymeddirectors.wa.gov/mobile.html. Last accessed 23 Mar 2015
VA/DoD Clinical Practice Guidelines (2010) Management of opioid therapy (OT) for chronic pain. Available at: www.healthquality.va.gov/guidelines/Pain/cot/. Last accessed 23 Mar 2015
Vieweg WV, Lipps WF, Fernandez A (2005) Opioids and methadone equivalents for clinicians. Prim Care Companion J Clin Psychiatry 7(3):86–88
Center to Advance Palliative Care. Methadone for the treatment of pain. Fast Fact #75. Available at: https://www.capc.org/fast-facts/75-methadone-treatment-pain/. Last accessed 23 Mar 2015
Waxman SA (2013) Clinical neuroanatomy, 27th edn. McGraw-Hill Education, New York
Lexi-Comp Online [Internet] (2015) Hudson, OH: Lexi-Comp. Last accessed and cited 23 Mar 2015 from institutional university access database
Hewitt DJ (2000) The use of NMDA-receptor antagonists in the treatment of chronic pain. Clin J Pain 16(2 Suppl):S73–S79
Drolet G, Dumont EC, Gosselin I, Kinkead R, Laforest S, Trottier JF (2001) Role of endogenous opioid system in the regulation of the stress response. Prog Neuropsychopharmacol Biol Psychiatry 25(4):729–741
Xi ZX, Stein EA (2002) GABAergic mechanisms of opiate reinforcement. Alcohol Alcohol 37(5):485–494
Bailey CP, Connor M (2005) Opioids: cellular mechanisms of tolerance and physical dependence. Curr Opin Pharmacol 5(1):60–68
Christie MJ (2008) Cellular neuroadaptations to chronic opioids: tolerance, withdrawal and addiction. Br J Pharmacol 154(2):384–396
Dang VC, Christie MJ (2012) Mechanisms of rapid opioid receptor desensitization, resensitization and tolerance in brain neurons. Br J Pharmacol 165(6):1704–1716
Morgan MM, Christie MJ (2011) Analysis of opioid efficacy, tolerance, addiction and dependence from cell culture to human. Br J Pharmacol 164(4):1322–1334
Pattinson KT (2008) Opioids and the control of respiration. Br J Anaesth 100(6):747–758
O’Connor RE, Brady W, Brooks SC et al (2010) Part 10: acute coronary syndromes: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation 122(18 Suppl 3):S787–S817
Krantz MJ, Martin J, Stimmel B, Mehta D, Haigney MC (2009) QTc interval screening in methadone treatment. Ann Intern Med 150(6):387–395
Hemstapat K, Monteith GR, Smith D, Smith MT (2003) Morphine-3-glucuronide’s neuro-excitatory effects are mediated via indirect activation of N-methyl-D-aspartic acid receptors: mechanistic studies in embryonic cultured hippocampal neurones. Anesth Analg 97(2):494–505, table of contents
Seifert CF, Kennedy S (2004) Meperidine is alive and well in the new millennium: evaluation of meperidine usage patterns and frequency of adverse drug reactions. Pharmacotherapy 24(6):776–783
Wood JD, Galligan JJ (2004) Function of opioids in the enteric nervous system. Neurogastroenterol Motil 16(Suppl 2):17–28
Rosow CE, Gomery P, Chen TY, Stefanovich P, Stambler N, Israel R (2007) Reversal of opioid-induced bladder dysfunction by intravenous naloxone and methylnaltrexone. Clin Pharmacol Ther 82(1):48–53
Suri A, Estes KS, Geisslinger G, Derendorf H (1997) Pharmacokinetic-pharmacodynamic relationships for analgesics. Int J Clin Pharmacol Ther 35(8):307–323
Lötsch J (2005) Pharmacokinetic-pharmacodynamic modeling of opioids. J Pain Symptom Manage 29(5 Suppl):S90–S103
Inturrisi CE, Colburn WA, Kaiko RF, Houde RW, Foley KM (1987) Pharmacokinetics and pharmacodynamics of methadone in patients with chronic pain. Clin Pharmacol Ther 41(4):392–401
Inturrisi CE, Portenoy RK, Max MB, Colburn WA, Foley KM (1990) Pharmacokinetic-pharmacodynamic relationships of methadone infusions in patients with cancer pain. Clin Pharmacol Ther 47(5):565–577
Lötsch J, Skarke C, Schmidt H, Grösch S, Geisslinger G (2001) The transfer half-life of morphine-6-glucuronide from plasma to effect site assessed by pupil size measurement in healthy volunteers. Anesthesiology 95(6):1329–1338
Martini C, Olofsen E, Yassen A, Aarts L, Dahan A (2011) Pharmacokinetic–pharmacodynamic modeling in acute and chronic pain: an overview of the recent literature. Expert Rev Clin Pharmacol 4(6):719–728
Mazoit JX, Butscher K, Samii K (2007) Morphine in postoperative patients: pharmacokinetics and pharmacodynamics of metabolites. Anesth Analg 105(1):70–78
Olofsen E, van Dorp E, Teppema L et al (2010) Naloxone reversal of morphine- and morphine-6-glucuronide-induced respiratory depression in healthy volunteers: a mechanism-based pharmacokinetic-pharmacodynamic modeling study. Anesthesiology 112(6):1417–1427
Scott JC, Cooke JE, Stanski DR (1991) Electroencephalographic quantitation of opioid effect: comparative pharmacodynamics of fentanyl and sufentanil. Anesthesiology 74(1):34–42
Scott JC, Stanski DR (1987) Decreased fentanyl and alfentanil dose requirements with age. A simultaneous pharmacokinetic and pharmacodynamic evaluation. J Pharmacol Exp Ther 240(1):159–166
Scott JC, Ponganis KV, Stanski DR (1985) EEG quantitation of narcotic effect: the comparative pharmacodynamics of fentanyl and alfentanil. Anesthesiology 62(3):234–241
Skarke C, Darimont J, Schmidt H, Geisslinger G, Lötsch J (2003) Analgesic effects of morphine and morphine-6-glucuronide in a transcutaneous electrical pain model in healthy volunteers. Clin Pharmacol Ther 73(1):107–121
Staahl C, Upton R, Foster DJ et al (2008) Pharmacokinetic-pharmacodynamic modeling of morphine and oxycodone concentrations and analgesic effect in a multimodal experimental pain model. J Clin Pharmacol 48(5):619–631
Yassen A, Kan J, Olofsen E, Suidgeest E, Dahan A, Danhof M (2006) Mechanism-based pharmacokinetic-pharmacodynamic modeling of the respiratory-depressant effect of buprenorphine and fentanyl in rats. J Pharmacol Exp Ther 319(2):682–692
Yassen A, Olofsen E, Romberg R et al (2007) Mechanism-based PK/PD modeling of the respiratory depressant effect of buprenorphine and fentanyl in healthy volunteers. Clin Pharmacol Ther 81(1):50–58
Shiran MR, Lennard MS, Iqbal MZ et al (2012) Pharmacokinetic-pharmacodynamic modeling of mood and withdrawal symptoms in relation to plasma concentrations of methadone in patients undergoing methadone maintenance treatment. J Clin Psychopharmacol 32(5):666–671
Boulton DW, Arnaud P, DeVane CL (2001) Pharmacokinetics and pharmacodynamics of methadone enantiomers after a single oral dose of racemate. Clin Pharmacol Ther 70(1):48–57
Murthy BR, Pollack GM, Brouwer KL (2002) Contribution of morphine-6-glucuronide to antinociception following intravenous administration of morphine to healthy volunteers. J Clin Pharmacol 42(5):569–576
Romberg R, Olofsen E, Sarton E, den Hartigh J, Taschner PE, Dahan A (2004) Pharmacokinetic-pharmacodynamic modeling of morphine-6-glucuronide-induced analgesia in healthy volunteers: absence of sex differences. Anesthesiology 100(1):120–133
Nakamura A, Hasegawa M, Ito H et al (2011) Distinct relations among plasma concentrations required for different pharmacological effects in oxycodone, morphine, and fentanyl. J Pain Palliat Care Pharmacother 25(4):318–334
Dyer KR, White JM, Foster DJ, Bochner F, Menelaou A, Somogyi AA (2001) The relationship between mood state and plasma methadone concentration in maintenance patients. J Clin Psychopharmacol 21(1):78–84
Florian J, Garnett CE, Nallani SC, Rappaport BA, Throckmorton DC (2012) A modeling and simulation approach to characterize methadone QT prolongation using pooled data from five clinical trials in MMT patients. Clin Pharmacol Ther 91(4):666–672
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Guthrie, S.K., Teter, C. (2016). Opioid Analgesics. In: Jann, M., Penzak, S., Cohen, L. (eds) Applied Clinical Pharmacokinetics and Pharmacodynamics of Psychopharmacological Agents. Adis, Cham. https://doi.org/10.1007/978-3-319-27883-4_11
Download citation
DOI: https://doi.org/10.1007/978-3-319-27883-4_11
Published:
Publisher Name: Adis, Cham
Print ISBN: 978-3-319-27881-0
Online ISBN: 978-3-319-27883-4
eBook Packages: MedicineMedicine (R0)